Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM)

Abstract only

Saved in:
Bibliographic Details
Published inJournal of clinical oncology Vol. 32; no. 15_suppl; p. 9010
Main Authors Flaherty, Keith, Daud, Adil, Weber, Jeffrey S., Sosman, Jeffrey Alan, Kim, Kevin, Gonzalez, Rene, Hamid, Omid, Infante, Jeffrey R., Cebon, Jonathan S., Schuchter, Lynn Mara, Long, Georgina V., Algazi, Alain Patrick, Kudchadkar, Ragini Reiney, Puzanov, Igor, Lawrence, Donald P., Kline, Amy S., Cunningham, Elizabeth Ann, Sun, Peng, Patel, Kiran, Kefford, Richard
Format Journal Article
LanguageEnglish
Published 20.05.2014
Online AccessGet full text

Cover

More Information
Summary:Abstract only
ISSN:0732-183X
1527-7755
DOI:10.1200/jco.2014.32.15_suppl.9010